Michael Gelband’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Michael Gelband’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-861	Closed	-$18K	–	2250
2022 Q3	$18K	Sell	861 -5,109	-86%	-$138K	﹤0.01%	1810
2022 Q2	$145K	Buy	5,970 +5,198	+673%	+$177K	﹤0.01%	1705
2022 Q1	$38K	Sell	772 -653	-46%	-$32.3K	﹤0.01%	2082
2021 Q4	$100K	Buy	+1,425	New	+$120K	﹤0.01%	1952
2021 Q3	–	Sell	-2,585	Closed	-$260K	–	2772
2021 Q2	$260K	Buy	2,585 +1,887	+270%	+$184K	﹤0.01%	1827
2021 Q1	$65K	Buy	+698	New	+$70.8K	﹤0.01%	2013
2019 Q4	–	Sell	-4,830	Closed	-$68K	–	1971
2019 Q3	$68K	Buy	+4,830	New	+$101K	﹤0.01%	1261
2019 Q2	–	Sell	-1,410	Closed	-$79K	–	1381
2019 Q1	$79K	Buy	+1,410	New	+$76.3K	0.01%	621

Other funds holding VBIV

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Michael Gelband's VBIV Position: Q4 2022 in Review

Michael Gelband sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q4 2022, closing a stake of 861 shares — an estimated $18K sold.

Michael Gelband first reported a position in VBIV in Q1 2019 and held it in 8 quarters. The position peaked at $260K in Q2 2021. 112 funds tracked by Wall St. Rank hold VBIV as of Q4 2022.

Michael Gelband reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q4 2022 after selling out during the quarter.
Michael Gelband sold 861 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q4 2022, an estimated $18K.
Michael Gelband first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q1 2019 and held it in 8 quarters.
Michael Gelband's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $260K in Q2 2021.
112 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q4 2022.

Based on ExodusPoint Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.